CRISPR Therapeutics AG
CRSP
$56.74
$0.060.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -103.80% | -75.99% | -77.61% | -138.43% | 32.23% |
| Total Depreciation and Amortization | -3.40% | -2.75% | -2.33% | -2.91% | -7.05% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 159.54% | 173.65% | 2.23% | -28.42% | -28.21% |
| Change in Net Operating Assets | 206.60% | -137.91% | 103.14% | 180.72% | -9.97% |
| Cash from Operations | -60.20% | -166.73% | -92.24% | 45.17% | 31.99% |
| Capital Expenditure | 72.70% | 81.42% | 80.57% | 79.93% | 84.02% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 108.05% | 97.36% | -221.01% | -172.52% | -257.49% |
| Cash from Investing | 107.87% | 96.99% | -227.30% | -174.87% | -266.72% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -7.91% | -88.64% | -89.78% | 430.53% | 1,252.95% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -7.78% | -88.62% | -89.91% | 429.78% | 1,251.17% |
| Foreign Exchange rate Adjustments | -94.49% | 2,625.00% | 3.33% | -128.77% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 120.11% | -838.26% | -230.16% | -151.58% | -1,133.23% |